Stem cell transplantation - GvHD
Overview of Presentations with access to videos on demand (EHA subscription needed)
LINKS TO ABSTRACTS:
Presentation ID p427-1
(S235) IBRUTINIB VS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN PATIENTS WITH NEW-ONSET CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND PHASE 3 INTEGRATE STUDY
Presenter: David Miklos, United States
The study authors conclude that in this randomized, placebo-controlled trial of ibrutinib in combination with corticosteroids for NIH-defined moderate/severe cGVHD, the primary endpoint did not meet statistical significance. However, numerical trends of improved clinical outcomes in the ibrutinib-pred arm were noted, including longer duration of response and event-free survival and improved patient-reported outcomes. Safety was consistent with the known profiles of ibrutinib and pred and was similar between treatment arms. According to the authors, the positive trends observed in other important clinical endpoints along with no additional safety trends and concerns suggest that ibrutinib may have value in some previously untreated pts with cGVHD.
Presentation ID p427-2
(S236) EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-HOST DISEASE AFTER CROSSOVER IN THE PHASE 3 REACH2 STUDY
Presenter: Jeff Szer, Australia
The study authors conclude that ruxolitinib led to high response rates in pts who crossed over from best available therapy to ruxolitinib. ORR and durable ORR were consistent with those seen with ruxolitinib during the randomized period. No new safety signals were observed in the crossover patients. These findings support the use of ruxolitinib in patients with steroid-refractory aGVHD who failed treatment with other systemic therapies.
Presentation ID p427-3
(S237) A PHASE 1 TRIAL OF THE HEDGEHOG SIGNALLING INHIBITOR GLASDEGIB IN PATIENTS WITH REFRACTORY SCLEROTIC CHRONIC GRAFT-VERSUS-HOST DISEASE
Presenter: Eduardo Rodríguez-Arbolí, Seville, Spain
The study authors conclude that low doses of glasdegib demonstrate high rates of clinical responses in heavily pretreated patients with sclerotic chronic GVHD, resulting in durable responses in one-third of the patients. Treatment schedule adjustments may be required in order to optimize tolerability.
Presentation ID p427-4
(S238) INTERIM RESULTS FROM THE EQUATE STUDY: PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE
Presenter: Lisette Acevedo, United States
The study authors conclude that the safety and efficacy observed to date and benefit-risk profile support continued study and evaluation in future randomized controlled trials.
Presentation ID p427-5
(S239) BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS HOST DISEASE AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE ROCKSTAR STUDY (KD025-213)
Presenter: Corey Cutler, Boston, United States
The study authors conclude that treatment with belumosudil was well tolerated at both doses and resulted in high ORRs across key subgroups, meeting the primary end point of this pivotal randomized trial in cGVHD. The note that responses were durable and clinically meaningful, irrespective of patient and cGVHD characteristics and organ involvement.